ERNA

Ernexa Therapeutics Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0000748592
$6.15 -6.25% $7.2M
High Impact Filing (7/10)
Vol
Market Cap$7.2M
Cap SizeNano Cap
Insider Activity2B / 0S
Insider Net $$2.0M
Reddit Sentiment42° Neutral
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0000748592·Prev Close $6.56

Recent Activity

Jun 9, 2026 other
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engin
May 27, 2026 SEC
Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, inclu
PRESS-RELEASE — Impact 4/10
May 6, 2026 Press
Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 bloc
Impact 5/10
Mar 31, 2026 Press
Ernexa Therapeutics announced preclinical success for its lead candidate ERNA-101 in ovarian cancer, with plans to submi
Impact 7/10
Mar 24, 2026 SEC
Ernexa Therapeutics has filed an S-3/A shelf registration, authorizing up to $50 million in securities offerings, includ
S-3/A — Impact 7/10
Feb 10, 2026 Insider
Cherington Charles bought 4,000,000 shares
10%+ Owner @ $0.5000 ($2.0M)
Feb 10, 2026 Insider
Cherington Charles bought 4,000,000 shares
10%+ Owner

Price Targets

No recent covering-analyst activity on file. No current recommendation available.
$30.00
Current $6.15 Low $30.00 Median $30.00 High $30.00 1 analysts
$30.00 $30.00

Analyst Ratings

Historical distribution0% buy · 6 analysts · no recent coverage
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-3.30 $-3.30 — $-3.30 1
Next Q $-3.84 $-3.84 — $-3.84 1
Current FY $-18.02 $-18.02 — $-18.02 1
Next FY $-1.86 $-1.86 — $-1.86 90% YoY 1

Latest Reports

NEUTRAL PRESS-RELEASE 4/10
Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, inclu
May 27, 2026
NEUTRAL Press 5/10
Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 bloc
May 6, 2026
BEARISH S-3/A 7/10
Ernexa Therapeutics has filed an S-3/A shelf registration, authorizing up to $50 million in securities offerings, includ
Mar 24, 2026

Recent Insider Trades

DateInsiderTypeValue
Feb 10, 2026Cherington CharlesBUY$2.0M
Feb 10, 2026Cherington CharlesBUY$0.00

Reddit Sentiment

42°▲
Neutral
Bearish Neutral Bullish
8 mentions 2 bullish 4 bearish
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

1 unique insiders with 2 transactions. Net insider value: $2.0M ($2.0M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Feb 10, 2026Cherington Charles10%+ OwnerBUY4,000,000$0.5000$2.0M
Feb 10, 2026Cherington Charles10%+ OwnerBUY4,000,000——
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
NEUTRAL PRESS-RELEASE 4/10
Ernexa Therapeutics provided a business update press release highlighting progress on its lead candi
May 27, 2026
BEARISH S-3/A 7/10
Ernexa Therapeutics has filed an S-3/A shelf registration, authorizing up to $50 million in securiti
Mar 24, 2026
NEUTRAL 5/10
Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, com
May 6, 2026
BULLISH 7/10
Ernexa Therapeutics announced preclinical success for its lead candidate ERNA-101 in ovarian cancer,
Mar 31, 2026
Historical analyst distribution: 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.

Analyst Price Targets

No recent covering-analyst activity on file. No current recommendation available.
$30.00 mean target
$30.00 Low $30.00 High
MetricValue
Current Price$6.15
Target Low$30.00
Target Mean$30.00
Target Median$30.00
Target High$30.00
# Analysts1
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-3.30 $-3.30 $-3.30 — — — $0.0B — 1
Next Q
2026-09-30
 $-3.84 $-3.84 $-3.84 — — — $0.0B — 1
Current FY
2026-12-31
 $-18.02 $-18.02 $-18.02 — — 0↑ 1↓ $0.0B — 1
Next FY
2027-12-31
 $-1.86 $-1.86 $-1.86 89.7% — 0↑ 1↓ $0.0B 0.0% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-3.300
7d ago$-2.110-1.190
30d ago$0.000-3.300
60d ago$0.000-3.300
90d ago$0.000-3.300

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Mar 1, 2023003120%
Feb 1, 2023003120%
Jan 1, 2023003120%
Dec 1, 2022003120%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

42°
Neutral
Bearish Neutral Bullish
8 mentions 2 bullish 4 bearish 8 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
May 19, 2026160° Warm101
May 19, 2026160° Warm101
May 13, 2026150° Neutral001
May 13, 2026150° Neutral001
May 6, 2026140° Cool011
May 6, 2026140° Cool011
Mar 13, 2026140° Cool011
Mar 13, 2026140° Cool011

Recent Reddit Threads

r/pennystocks Bullish 24d 21h ago
$PPCB - The next post-split micro-float runner? Setup mirrors ERNA, HCAI, and AKAN before they ripped
▲ 1 💬 1 ⚡ 0.5
r/stocks Neutral 1mo ago
Why the pop in $ERNA today?
▲ 1 💬 0 ⚡ 0.5
r/pennystocks Bearish 1mo ago
$ERNA +30% — absolute survival in ovarian cancer mouse models on 818K float
▲ 1 💬 1 ⚡ 0.5
r/pennystocks Bearish 3mo ago
$ERNA: Overblown Fear + Warrant Target Play = 2X Potential Gains
▲ 1 💬 1 ⚡ 0.5
Jun 9, 2026
other
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in o
May 27, 2026
earnings
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company <
May 20, 2026
other
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
<p align="center"><em>Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current t
May 15, 2026
short_volume
Short Volume: ERNA — 58.0% short (0.4M / 0.8M)
Short: 449,536 | Exempt: 112,311 | TRF Vol: 775,422 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: ERNA — 115,056 shares ($1.4M) failed to deliver
Settlement: 20260514, Price: $12.14, FTD Value: $1,396,779.84, ERNEXA THERAPEUTICS INC. COM P
May 13, 2026
short_interest
FTD: ERNA — 180,404 shares ($2.2M) failed to deliver
Settlement: 20260513, Price: $12.01, FTD Value: $2,166,652.04, ERNEXA THERAPEUTICS INC. COM P
May 12, 2026
short_volume
Short Volume: ERNA — 56.3% short (6.0M / 10.6M)
Short: 5,977,340 | Exempt: 948,993 | TRF Vol: 10,624,626 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_interest
FTD: ERNA — 226,761 shares ($1.6M) failed to deliver
Settlement: 20260512, Price: $7.21, FTD Value: $1,634,946.81, ERNEXA THERAPEUTICS INC. COM P
May 11, 2026
other
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
<p align="center"><em>Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape </em></p
May 11, 2026
short_interest
FTD: ERNA — 296,659 shares ($2.2M) failed to deliver
Settlement: 20260511, Price: $7.53, FTD Value: $2,233,842.27, ERNEXA THERAPEUTICS INC. COM P
May 8, 2026
short_interest
FTD: ERNA — 444,960 shares ($3.5M) failed to deliver
Settlement: 20260508, Price: $7.82, FTD Value: $3,479,587.2, ERNEXA THERAPEUTICS INC. COM P
May 7, 2026
short_volume
Short Volume: ERNA — 55.4% short (2.6M / 4.7M)
Short: 2,617,378 | Exempt: 15,086 | TRF Vol: 4,724,409 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_interest
FTD: ERNA — 584,561 shares ($3.5M) failed to deliver
Settlement: 20260507, Price: $6.04, FTD Value: $3,530,748.44, ERNEXA THERAPEUTICS INC. COM P
May 6, 2026
fda
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value <pre>Landma
May 6, 2026
short_volume
Short Volume: ERNA — 59.3% short (17.1M / 28.9M)
Short: 17,122,245 | Exempt: 166,137 | TRF Vol: 28,871,143 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)